%0 Journal Article
%T Risk of significant cytopenias after treatment with tocilizumab in systemic juvenile arthritis patients with a history of macrophage activation syndrome
%A Kessler Elizabeth A
%A Vora Sheetal S
%A Verbsky James W
%J Pediatric Rheumatology
%D 2012
%I BioMed Central
%R 10.1186/1546-0096-10-30
%X Tocilizumab (TCZ) is the first FDA- approved treatment for systemic juvenile idiopathic arthritis (sJIA). We report 3 cases of cytopenias in children with sJIA treated with TCZ. Two of the children who developed significant cytopenias shortly after initiation of TCZ had a history of macrophage activation syndrome. We raise the possibility that patients with a tendency towards MAS have an increased risk of developing cytopenias when treated with tocilizumab.
%K Juvenile idiopathic arthritis
%K Macrophage activation syndrome
%K Tocilizumab
%U http://www.ped-rheum.com/content/10/1/30